A Phase 2 interventional study of BOTOX Dose A and Placebo for BOTOX in Ventral Hernia and Abdominal Hernia, sponsored by AbbVie. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Hernia, Ventral with a site in United States — 14 open to participants now, 24 under way, none of them phase 3. Hernia, Ventral · United States.
Among the 94 studies in Hernia, Ventral with a site in United States, this one is the 64th largest by enrollment of the 70 interventional ones that give a count, is one of 8 that started in 2024, is one of 3 in phase 2, and was the 68th registered.
230 studies on the registry are indexed under Hernia, Ventral; 45 are open to participants now.
Browse Hernia, Ventral studies →14 of the 94 studies in Hernia, Ventral with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18–80
AbbVie · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Lucas Beffa · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hernia, Ventral studies recruiting now, 19 (73%) set no upper age limit and 4 (15%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 70 interventional studies, 63 across the 24 observational. Of the 59 that completed or were terminated, 31 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 94 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Hernia, Ventral — fewer than ten, so there is no comparison to draw.
10 of the studies in Hernia, Ventral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04718168W.L.Gore & AssociatesGORE® ENFORM Biomaterial Product Study | 2026-12 |
| NCT07639281Tori DotsonOpioid Education Ventral Hernia Repair | 2026-12 |
| NCT07874724University of South FloridaCryoneurolysis for Abdominal Wall Relaxation Prior to Ventral Hernia Repair | 2027-03-01 |
| NCT04779918Tela Bio IncVentral or Inguinal Hernia, Robotically Repaired With OviTex Mesh | 2027-03-30 |
| NCT06874413Prisma Health-UpstateTargeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Ventral Hernia Repair | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hernia, Ventral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventral hernias form when there is a loss of integrity of the abdominal wall muscles. Abdominal hernias can expand and can cause severe pain as the abdominal wall weakens. The purpose of this study is to evaluate the safety and efficacy of a range of onabotulinumtoxinA (BOTOX) doses to achieve primary fascial closure (PFC) without use of component separation technique (CST) in ventral hernia surgical repair.
BOTOX is an investigational drug being developed for the treatment of ventral hernias. In this dose escalation study, participants will be placed in 1 of 3 cohorts. Cohort 1 will be randomized to receive placebo or 1 of 2 BOTOX doses, after which time Cohort 2 will be randomized to receive placebo or 1 of 3 BOTOX doses. Participants in Cohort 3 will be randomized to receive placebo or 1 of 3 BOTOX doses. Adult participants undergoing open abdominal ventral hernia repair will be enrolled. Around 200 participants will be enrolled in the study at approximately 20 sites in the United States.
Participants will receive a single intramuscular injection of BOTOX Dose A, BOTOX Dose B, BOTOX Dose C, or placebo.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will be followed for approximately 3 months after surgery and will receive a follow-up phone call 30 days (+/-) their last study visit. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant meets the following disease activity criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive BOTOX Dose A
Drug: BOTOX Dose A
Participants will receive BOTOX Dose B.
Drug: BOTOX Dose B
Participants will receive placebo for BOTOX.
Drug: Placebo for BOTOX
Participants will receive BOTOX Dose A
Drug: BOTOX Dose A
Participants will receive BOTOX Dose B
Drug: BOTOX Dose B
Participants will receive BOTOX Dose C
Drug: BOTOX Dose C
Participants will receive placebo for BOTOX
Drug: Placebo for BOTOX
Participants will receive BOTOX Dose A
Drug: BOTOX Dose A
Participants will receive BOTOX Dose B.
Drug: BOTOX Dose B
Participants will receive BOTOX Dose C.
Drug: BOTOX Dose C
Participants will receive placebo for BOTOX.
Drug: Placebo for BOTOX
Injection; intramuscular
Also known as: OnabotulinumtoxinA
Placebo
Injection; intramuscular
Also known as: OnabotulinumtoxinA
Injection; intramuscular
Also known as: OnabotulinumtoxinA
Percentage of participants with achievement of primary fascial closure (PFC) without the use of component separation techniques (CST) in open ventral hernia surgical repair
PFC will be defined as the ability to achieve fascia to fascia midline approximation. CST will be defined as the release of the external oblique muscle or the transection of transversus abdominis muscle (known as posterior component separation with transversus abdominis release (TAR).
Time frame: Up to 4 Months
Percentage of participants with achievement of PFC
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Time frame: Up to 4 Months
Percentage of participants with usage of CST for the purpose of PFC
CST will be defined as the release of the external oblique muscle or the transection of transversus abdominis muscle (known as posterior component separation with transversus abdominis release (TAR).
Time frame: Up to 4 Months
Number of lateral abdominal wall muscles released among participants who required CST use to achieve PFC as reported by the operating surgeon
Lateral abdominal wall muscles are released by TAR and external oblique release (unilateral or bilateral)
Time frame: Up to 4 Months
Change in length of lateral abdominal wall complex
Change in length of lateral abdominal wall complex as measured by abdominal CT scan in supine position prior to surgical repair will be assessed.
Time frame: Up to 4 Months
Change in Width to the Hernia Defect
Change from screening in width to the hernia defect as measured by abdominal CT scan in supine position prior to surgical repair will be assessed.
Time frame: Up to 4 Months
Change from screening in length of lateral abdominal wall complex
Change from screening in length of lateral abdominal wall complex as measured by abdominal CT scan performing Valsalva maneuver prior to surgical repair will be assessed.
Time frame: Up to 4 Months
Change from screening in width to the hernia defect
Change from screening in width to the hernia defect as measured by abdominal CT scan performing Valsalva maneuver prior to surgical repair
Time frame: Up to 4 Months
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Start is estimated for May 2024; primary completion for Apr 2025, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A